Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Bausch Health Companies Inc. (NYSE:BHC) have earned an average rating of “Reduce” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $7.42.

A number of analysts recently issued reports on BHC shares. Royal Bank of Canada reduced their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th.

Institutional Trading of Bausch Health Companies

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mountain Hill Investment Partners Corp. acquired a new position in shares of Bausch Health Companies during the 4th quarter valued at about $56,000. Bank of Nova Scotia bought a new stake in Bausch Health Companies during the fourth quarter worth approximately $83,000. One68 Global Capital LLC acquired a new position in Bausch Health Companies during the fourth quarter valued at approximately $90,000. Balyasny Asset Management L.P. acquired a new position in Bausch Health Companies during the fourth quarter valued at approximately $97,000. Finally, Alpine Global Management LLC bought a new position in shares of Bausch Health Companies in the fourth quarter valued at approximately $114,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Price Performance

NYSE BHC opened at $7.21 on Friday. The firm has a market capitalization of $2.65 billion, a price-to-earnings ratio of -60.04, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59. The company has a 50 day simple moving average of $7.32 and a 200-day simple moving average of $7.60. Bausch Health Companies has a 52-week low of $3.96 and a 52-week high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The company had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.51 billion. On average, analysts predict that Bausch Health Companies will post 4.41 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.